Published: May 17, 2018

Introduction {#sec1}
============

Hematopoietic stem cells (HSCs) are multipotent progenitors that sustain blood production from embryonic development to adulthood. Currently, *ex vivo* HSC expansion and HSC generation from induced pluripotent stem cells are the limiting factors toward achieving personalized cell-based regenerative medicine, creating a need to fully understand the signaling pathways involved in these processes. Definitive hematopoiesis development is very conserved in vertebrates. In both zebrafish and mammals, after primitive hematopoiesis has emerged, definitive hematopoiesis occurs in two waves: first, transient erythro-myeloid precursors (EMPs) arise in the yolk sac and posterior blood island, from mice ([@bib3]) and zebrafish ([@bib4]), respectively. Then, HSCs are specified from the aortic hemogenic endothelium. In the mouse embryo, HSC specification occurs along the ventral aspect of large arteries, predominantly in the aorta-gonads-mesonephros (AGM) region ([@bib5], [@bib7], [@bib47]) between embryonic (E) day 9.5 and 11.5. In the zebrafish, HSCs are born at 32--60 hr post fertilization (hpf), from the hemogenic endothelium located in the dorsal aorta ([@bib2], [@bib20]). As the embryo makes a limited number of HSCs, they migrate to a first niche that will allow their expansion. In mouse, this initial expansion occurs in the fetal liver ([@bib12]), whereas zebrafish HSCs colonize the caudal hematopoietic tissue (CHT) ([@bib36]). In both models, HSCs interact with endothelial cells (ECs) that promote their proliferation ([@bib18], [@bib36]). We, and others, have shown that this expansion depends on several cytokines produced by stromal cells and caudal ECs (cECs) ([@bib21], [@bib36]).

Many studies performed in the mouse model demonstrated the importance of the *cKit/KitL* pathway in HSC maintenance *in vivo*, or HSC expansion *ex vivo* ([@bib11], [@bib28]). However, little is known about the role of *Kit* signaling during the emergence of definitive hematopoiesis in the mouse embryo. In zebrafish, the role of *kit* in hematopoiesis still remains unclear. The zebrafish genome encodes two paralogs, *kita* and *kitb*, following genome duplication and possible sub-functionalization ([@bib22]). *Kita*, but not *kitb*, is important for pigmentation and melanocyte development ([@bib16]) and appears not to be required for hematopoiesis, as adult *sparse* mutants (*kita*^*−/−*^) show normal adult hematopoiesis ([@bib30]). Similarly, there are two paralogs for the stem cell factor (*kit-ligand*): *kitlga* is important for melanocyte normal development and, interestingly, *kitlgb* is expressed in the posterior blood island at 24 hpf ([@bib16]), strongly suggesting a role for this gene in zebrafish hematopoiesis. Furthermore, we recently showed that *kitlgb* could rescue the loss of HSCs observed in *tfec* mutants ([@bib21]). *KITL* also plays a major role in the expansion of human HSCs *ex vivo* but always in conjunction with other cytokines. Current clinical protocols targeting human HSCs for gene therapies usually use a cytokine cocktail composed of *KITL*, *FLT3L*, and *TPO* ([@bib6], [@bib31], [@bib32]). However, other cytokines seem to be potent to expand HSCs, such as human Oncostatin M (*OSM*). Oostendorp and colleagues showed that *KITL* together with *OSM*, but not by itself, could promote the expansion of immature human cord-blood HSPCs and improve repopulating activity in NOD/SCID mice ([@bib28]). *OSM* mediated these effects by downregulating the *KITL*-induced MAPK/ERK pathway to preserve high CD34 expression ([@bib28]). This was further corroborated by studies showing that AGM hematopoiesis was enhanced *in vitro* by media containing a mix of *KIT*, *OSM*, *LIF*, and *FGF* ([@bib26]).

*OSM* is a cytokine belonging to the IL-6 family and has pleiotropic actions in hematopoiesis, inflammation, and neural development ([@bib23], [@bib33], [@bib39]). *Osm* binds a heterodimer that combines the *OSM* receptor chain (*OSMR*) and the signaling gp130 chain, which induces the intracellular activation of the JAK/STAT and MAPK pathways ([@bib10]). *OSM* is expressed in a range of hematopoietic tissues, including thymus, bone marrow (BM), and spleen, and plays a role in the maintenance of hematopoietic progenitors through cell and non-cell autonomous mechanisms ([@bib35], [@bib37], [@bib38]). BM transplantation studies have shown that BM from wild-type (WT) mice transplanted into *Osmr*-deficient mice results in reduced erythrocytic/megakaryocytic progenitors. The same effect is observed when BM from *Osmr*-deficient mice is transplanted into WT mice ([@bib38]). In contrast, ectopic overexpression of *Osm* resulted in enhanced extra-medullary hematopoiesis and increased megakaryocyte and platelet production ([@bib43]). Moreover, *Osm*-deficient mice show a reduced thymus size as well as an accumulation of apoptotic thymocytes, suggesting that a fine balance of *Osm* signaling is required for correct thymocyte development ([@bib13]).

In this study, we show that *kitb/kitlgb*, but not *kita/kitlga*, is required for HSC specification, emergence, and expansion in the CHT. We also identified the zebrafish ortholog *osm*, and characterized the function of this cytokine in zebrafish hematopoiesis. By combining different approaches, we show that zebrafish *osm* retains similar function to its mammalian ortholog and can expand HSCs, but also inhibits lymphoid commitment. We also show that interfering with *osmr* results in an early block in the specification of the hemogenic endothelium. Finally, we show that *osm* and *kitlgb* synergistically enhance HSC proliferation and decrease HSC differentiation.

Results {#sec2}
=======

*Kitb*, but Not *kita*, Signaling Is Necessary for HSC Specification {#sec2.1}
--------------------------------------------------------------------

To understand the roles of *kita* and *kitb* in zebrafish HSC biology, we examined their expression during definitive hematopoiesis. In fluorescence-activated cell sorting (FACS)-sorted hematopoietic progenitors (EMPs and HSCs), we found that *kita* was mildly enriched in HSCs but found a much higher enrichment of *kitb* in both EMPs and HSCs ([Figure 1](#fig1){ref-type="fig"}A), although HSC enrichment was not significant compared with the whole embryo ([Figure 1](#fig1){ref-type="fig"}A). To further study these signaling pathways, we injected full-length mRNA for *kitlga* or *kitlgb* and knocked down the expression of *kita* and *kitb* using morpholinos ([Figures S1](#mmc1){ref-type="supplementary-material"}A--S1D). The injection of *kitlga* and *kitlgb* mRNA did not alter *cmyb* expression at 4 days post fertilization (dpf) ([Figure 1](#fig1){ref-type="fig"}B). However, *kitb* morphants showed reduced *cmyb* expression at 4 dpf ([Figure 1](#fig1){ref-type="fig"}B) and reduced *rag1* expression at 4.5 dpf ([Figure S1](#mmc1){ref-type="supplementary-material"}G). This loss of *cmyb* signal (i.e., loss of HSPCs in the CHT) likely resulted from a defect in HSC specification in *kitb* morphants, as shown by reduced levels of *runx1* and *cmyb* along the aorta at 28 and 36 hpf, respectively ([Figure 1](#fig1){ref-type="fig"}C). However, *gata2b* expression at 22 hpf was maintained in *kitb* morphants, indicating that specification of the hemogenic endothelium is not dependent on *kitb* signaling ([Figure 1](#fig1){ref-type="fig"}C). In contrast, the expression of *gata2b* at 22 hpf, *runx1* at 28 hpf, and *cmyb* at 36 hpf was normal in *kita* morphants ([Figure 1](#fig1){ref-type="fig"}C). The hematopoietic phenotype observed in *kitb* morphants was identical in *kiltgb* morphants ([Figures 1](#fig1){ref-type="fig"}D, [S1](#mmc1){ref-type="supplementary-material"}E, and S1F). Both *kita* and *kitb* morphants displayed normal primitive myelopoiesis as detected by *mfap4* (primitive macrophages) and *mpx* (primitive neutrophils) expression ([Figure S1](#mmc1){ref-type="supplementary-material"}H). Some *kitb* morphants had a modest reduction in primitive erythrocytes ([Figure S1](#mmc1){ref-type="supplementary-material"}H) and some showed disrupted vasculature development (n = 5/12, data not shown). We also confirmed that *kitlga* mRNA injection resulted in hyper-pigmentation, while *kita* morphants had a reduction in the number of melanocytes over the yolk ball ([Figures S1](#mmc1){ref-type="supplementary-material"}I--S1K), in agreement with previous studies ([@bib16]). In contrast, embryos injected with either *kitlgb* mRNA or the *kitb* morpholino showed no alteration of their pigmentation pattern ([Figures S1](#mmc1){ref-type="supplementary-material"}I--S1K). We therefore conclude that *kita/kitlga* signaling is not required for definitive hematopoiesis but only for melanocyte development as previously suggested. We also conclude that *kitb/kitlgb* signaling is required for proper HSC specification, likely at the cell autonomous level, but one cannot exclude a non-cell autonomous mechanism, as a consequence of our qPCR data. Moreover, *kitlgb* gain of function by itself cannot increase HSC expansion, as we previously observed ([@bib21]). Therefore, we looked for a cytokine that could interact with *kitlgb* to promote HSC expansion.Figure 1*kitb*, but Not *kita*, Signaling Is Necessary for Correct HSC Specification(A) qPCR expression of *kita* and *kitb* in FACS-sorted hematopoietic progenitors. *Kita* whole and EMPS, p = 0.14. *kita* whole and HSCs, p \< 0.0001. *kitb* whole and EMPs, p = 0.023. *kitb* whole and HSCs, p = 0.14. EMPs: double-positive *lmo2:eGFP*, *gata1:DsRed* cells (28 hpf) ([@bib4]). HSCs: double-positive *flk1:mCherry*, *cmyb:eGFP* cells (36 hpf) ([@bib2]). Data are from biological triplicates. Data are means ± SD.(B) *cmyb* ISH at 4dpf in non-injected control (NI), *kitlga* (injected at 500 pg throughout, unless stated) or *kitlgb* (injected at 200 pg throughout, unless stated) mRNA injected embryos. *cmyb* was socred at 4dpf following ctrl-MO, *kita*-MO (injectedat 3 ng throughout, unless stated) or *kitb*-MO (injected at 8 ng throughout, unless stated) injection. NI, non-injected control*. +kitlga/kitlgb*, *kitlga/kitlgb* full length mRNA injected embryos.(C) Control-MO, *kita*-MO and *kitb*-MO injected embryos were scored for the expression of *gata2b, runx1* and *cmyb* at 22 hpf, 28 hpf and 36 hpf, respectively. (D) *kitlgb* morphants were scored for *gata2b, runx1* and *cmyb* at 22 hpf, 28 hpf and 4 dpf, respectively. Analysis was completed using ordinary one way ANOVA with multiple comparisons. \*\*\*\* p \< 0.0001; \*p \< 0.05; NS, p \> 0.05. All scale bars, 100 µm.

Identification of Zebrafish *osm* {#sec2.2}
---------------------------------

Based on previous human studies, we wanted to investigate the synergy between *osm* and *kitlgb* ([@bib28]). However, no ortholog was annotated in the zebrafish genome. To identify *osm*, we proceeded by synteny analysis. The mouse and human *OSM* orthologs both lie in close proximity to *Gatsl* and *GATSL3*, respectively. In the zebrafish genome, we found a homologous transcript lying in close proximity to *gatsl3* ([Figure S2](#mmc1){ref-type="supplementary-material"}A). This gene, annotated *si:ch73-47f2.1*, encodes a protein that segregates with the mouse and human *OSM* by phylogeny analysis but not with the other cytokines tested ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Furthermore, when we compared the gene structures of human *OSM*, mouse *Osm*, and zebrafish *si:ch73-47f2.1*, we found a similar arrangement consisting of three exons ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Amino acid similarity was low (26.3% with mouse *Osm*, 24.7% with human *OSM*, using EMBOSS Needle), but this has been previously noted in the characterization of other zebrafish cytokines when compared with their mammalian orthologs, such as *epo*, which shows 32% identity and 50% similarity between zebrafish and humans ([@bib9]). Finally, *si:ch73-47f2.1* encodes a protein that contains a four-helical cytokine-like domain that is highly conserved with the mouse and human proteins ([Figure S2](#mmc1){ref-type="supplementary-material"}D). We therefore conclude that *si:ch73-47f2.1* could be the zebrafish ortholog of the mammalian *OSM*. To further explore this hypothesis we examined the expression of *si:ch73-47f2.1/osm* and its receptor (*osmr*) and then examined their function during HSC ontogeny.

As the expression of *osm* was not detectable by *in situ* hybridization (ISH) (data not shown), we isolated cECs by FACS and performed qPCR. We found an enrichment of *osm* in the CHT vasculature compared with vasculature sorted from the rest of the embryo ([Figures 2](#fig2){ref-type="fig"}A and A′). Furthermore, *osmr* seemed highly enriched in definitive hematopoietic progenitors, EMPs and HSCs, compared with the whole embryo even if statistical significance was not reached ([Figure 2](#fig2){ref-type="fig"}B). In contrast, *gp130* was expressed rather ubiquitously ([Figure 2](#fig2){ref-type="fig"}C). Therefore, in zebrafish, as in mammals, the expression of *osm* and its receptor strongly correlates with a role in hematopoiesis. We next investigated the roles of this pathway in zebrafish HSCs.Figure 2*osm* Expands HSCs within the CHT Niche(A and A′) Experimental outline and qPCR expression of *osm* from whole zebrafish or FACS-sorted ECs. Data are biological triplicates plated in technical duplicates.(B and C) qPCR expression of *osm*, *osmr*, and *gp130* (*il6st* in zebrafish) in whole zebrafish or FACS-sorted hematopoietic progenitors (EMPs and HSCs). All qPCR data are from biological triplicates. In (A′), (B), and (C), analysis was performed by a one-way ANOVA with multiple comparisons. In (A′), whole and heads, p = 0.16; whole and tails, p = 0.0004; heads and tails, p = 0.0019. In (B), whole and EMPs, p = 0.17; whole and HSCs, p = 0.14. In (C), whole and EMPs, p = 0.22; whole and HSCs, p = 0.98.(D and E) ISH expression of *cmyb*, *flk1*, and *runx1* following injection of full-length *osm* mRNA (injected at 300 pg here and throughout, unless otherwise stated) or in non-injected embryos. Scale bar, 100 μm.(F) Imaging area.(G and G′) Imaging double transgenic *flk1:mCherry/cmyb:GFP* embryos at 3 and 4 dpf. Arrowheads represent HSCs embedded in the CHT niche. Scale bar, 100 μm. In (G′), between NI and *osm* injected at 3 dpf, p = 0.0097, and at 4 dpf, p = 0.4894.(H) Imaging area.(I and I′) anti-GFP and pH3 immunofluorescence at 3 dpf in *cmyb:eGFP* embryos. Arrows represent double-positive, proliferating cells. Scale bar, 25 μm. Analysis was performed by an unpaired, two-tailed Student\'s t test in (G′) and (I′). In (I′), p = 0.0050. NI, non-injected control. *+osm*, *osm* full-length mRNA-injected embryos. All data are means ± SD ^∗∗∗^p \< 0.001, ^∗∗^p \< 0.01, NS, p \> 0.05.

*osm* Signaling Is Sufficient to Expand HSCs {#sec2.3}
--------------------------------------------

Previous studies have reported that human *OSM* is capable of expanding human HSCs while inhibiting lymphoid differentiation ([@bib19], [@bib28]). When we overexpressed *osm* by mRNA injection, we found a consistent increase in *cmyb* expression in the CHT compared with non-injected controls at 4 dpf ([Figure 2](#fig2){ref-type="fig"}D). *osm* mRNA injection did not change *runx1* or *flk1* expression at 26 hpf, and therefore did not increase HSC specification ([Figure 2](#fig2){ref-type="fig"}E). We then focused on HSCs within the niche using *flk1:mCherry;cmyb:eGFP* double transgenic embryos ([@bib21], [@bib36]) and found an increase in the number of HSCs within the niche at 3 dpf after *osm* gain of function compared with non-injected control embryos ([Figures 2](#fig2){ref-type="fig"}F--2G′). By 4 dpf, this increase was minimal and was close to control levels ([Figures 2](#fig2){ref-type="fig"}F--2G′). We then used *cmyb*:*GFP* embryos and stained for GFP and phospho-histone 3 (pH3), a marker of cell division, by immunofluorescence. Embryos injected with *osm* mRNA exhibited a significant increase in the number of proliferating HSCs within the CHT at 3 dpf ([Figure 2](#fig2){ref-type="fig"}H--2I′). Therefore, we conclude that the *osm* signaling pathway expands HSCs within the CHT by augmenting their proliferation, a result that was very similar to our previous work where we overexpressed *tfec* mRNA ([@bib21]). Accordingly, we found that *osm* expression was augmented in cECs after *tfec* overexpression ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Furthermore, *osm* overexpression could rescue the loss of *cmyb* expression observed in *tfec* mutants ([Figures S3](#mmc1){ref-type="supplementary-material"}B and S3B′), supporting our conclusion that *osm* plays a role in expanding HSCs within the niche. We next examined the effect of *osm* on HSC differentiation.

*osm* Inhibits Lymphocyte Differentiation by Reducing Lymphoid Gene Expression {#sec2.4}
------------------------------------------------------------------------------

Previous studies showed that *OSM* suppresses commitment to the lymphoid fate ([@bib19]). We observed that *osm* mRNA injection decreased the thymus size at 4.5 dpf, indicating a decrease in HSC differentiation to the T cell lineage ([Figure 3](#fig3){ref-type="fig"}A). To further examine this, we took advantage of the *ikaros:eGFP* transgenic line that marks lymphoid precursors ([@bib15]). First, we found a decreased number of lymphoid progenitors in the thymus in *osm*-injected embryos at 4.5 dpf ([Figure S4](#mmc1){ref-type="supplementary-material"}A), suggesting a defect in thymic colonization. To understand this decrease, we examined the CHT of embryos at 48 hpf when lymphoid precursors are just beginning to seed the thymus ([@bib24]). At this stage, there is a distinct GFP^high^ population and many, more difficult to define GFP^low^ cells within the CHT. Injection of *osm* mRNA resulted in a severe decrease in the number of GFP^high^ cells at 48 hpf in the CHT ([Figures 3](#fig3){ref-type="fig"}B and 3C) probably resulting in the defect of thymic colonization observed at 4.5 dpf ([Figure S4](#mmc1){ref-type="supplementary-material"}A). To further characterize the *ikaros:GFP*^*high*^ and *GFP*^*low*^ populations, we sorted these subsets from isolated tails dissected from control *ikaros:eGFP* embryos. We then investigated their gene expression pattern by qPCR ([Figures S4](#mmc1){ref-type="supplementary-material"}B). *Ikaros*-GFP^high^ cells expressed high levels of *gata3*, *cmyb*, *ccr9a*, and *irf4a*. We therefore defined these cells as lymphoid-primed or lymphoid-committed HSCs ([Figures S4](#mmc1){ref-type="supplementary-material"}C--S4P), according to previous results showing that *irf4a* is required for lymphoid commitment ([@bib44]). Interestingly, both populations expressed high levels of *kitb* and *osmr* ([Figures S4](#mmc1){ref-type="supplementary-material"}O and S4P).Figure 3*osm* Inhibits Lymphocyte Priming and Differentiation by Repressing Lymphoid Gene Expression(A) ISH at 4.5 dpf of *rag1* thymus staining with quantification of thymus area, where p = 0.0087. Scale, 50 μm.(B) Live imaging of CHT region in *ikaros:eGFP* embryos at 48 hpf. Each arrow indicates a single *ikaros:eGFP*^*high*^ cell. Scale, 100 μm.(C) Quantification of the number *of ikaros:eGFP*^*high*^ cells at 48 hpf, p = 0.0028.(D) FACS sorting and analysis of *ikaros:eGFP*^*high*^ cells at 48 hpf (p = 0.0112). Values indicated on FACS plots are mean ± SEM, graphs are means ± SD.(E) Quantification of *ikaros:eGFP*^*high*^ cells.(F--I) qPCR analysis of *il7r* (F) (p = 0.0017), *irf4a* (G) (p = 0.0001), *ccr9a* (H) (p = 0.1265), and *ikaros* (I) (p = 0.8030) expression in *ikaros:eGFP*^*high*^ cells FACS sorted at 48 hpf. qPCR data shown are the mean ± SEM of three data points, calculated from three independent experiments. Each separate experiment was conducted in biological triplicates, then averaged to give a single value. NI, non-injected control. *+osm*, *osm* full-length mRNA-injected embryos. Statistical analysis was completed using an unpaired, two-tailed Student\'s t test. ^∗∗∗^p \< 0.001; ^∗∗^p \< 0.01; ^∗^p \< 0.05; NS, p \> 0.05.

To understand the defect in thymic hematopoiesis, we FACS sorted GFP^high^ cells from non-injected or *osm* mRNA-injected *ikaros:eGFP* embryos and measured, by qPCR, the expression levels of lymphoid genes ([Figure 3](#fig3){ref-type="fig"}D). First, in embryos injected with *osm* mRNA, we found a decrease in the percentage of GFP^high^ cells suggesting that *osm* inhibits HSC differentiation toward the lymphoid lineage ([Figure 3](#fig3){ref-type="fig"}E), concordant with our microscopy observations ([Figure 3](#fig3){ref-type="fig"}B). Second, we saw a decrease in the expression of *il7r*, *ccr9a*, and *irf4a* (although the decrease in *ccr9a* was not significant) ([Figures 3](#fig3){ref-type="fig"}F--3I), three important transcripts for T lymphopoiesis, but no change in *gata3*, *cmyb*, or *runx1*, three genes normally expressed in HSCs ([Figures S3](#mmc1){ref-type="supplementary-material"}C and S3D). Therefore, *osm* not only expands HSCs but also inhibits their differentiation toward the lymphoid lineage by reducing the expression of several lymphoid receptors and transcription factors necessary for migration to and maturation in the thymus. Of note, the decrease in the number of *ikaros*^*high*^ cells in the CHT ([Figures 3](#fig3){ref-type="fig"}B and 3C) might have an additional explanation as it is also possible that *osm* acts directly upon the lymphoid-committed T cell progenitors that arise directly from the hemogenic endothelium ([@bib41]). However, *osm* overexpression did not alter definitive erythropoiesis and granulopoiesis ([Figure S3](#mmc1){ref-type="supplementary-material"}E--S3G), but the number of macrophages was slightly reduced ([Figure S3](#mmc1){ref-type="supplementary-material"}F) in the CHT. We next inhibited *osmr* signaling to fully define the role of this signaling pathway in zebrafish hematopoiesis.

*osmr* Signaling Is Necessary for Early HSC Specification {#sec2.5}
---------------------------------------------------------

During mouse embryogenesis, *Osm* is important for HSC emergence and may act at the level of the hemogenic endothelium ([@bib23]). *Osm* is also required for adult erythrocyte and megakaryocyte differentiation ([@bib38]). We targeted *osmr* signaling by morpholino injection ([Figures S5](#mmc1){ref-type="supplementary-material"}A--S5D). Compared with control embryos, *osmr* morphants exhibited an almost complete loss of aortic *gata2b*, *runx1*, and *cmyb* at 22 hpf, 28 hpf, and 36 hpf, respectively ([Figure 4](#fig4){ref-type="fig"}A). As a consequence, *cmyb* expression was completely lost in the CHT at 4 dpf and *rag1* was either severely reduced or completely lost at 4.5 dpf ([Figures 4](#fig4){ref-type="fig"}B and 4C). *Flk1*, *flt4*, and *dlc* expression was, however, normal in the aorta in *osmr* morphants at 28 hpf, indicating normal vessel specification ([Figure S6](#mmc1){ref-type="supplementary-material"}A). *Osmr* morphants also showed reduced red blood cell circulation at 48 hpf (n = 16/20, [Video S2](#mmc3){ref-type="supplementary-material"}) compared with control morphants (n = 10/10, [Video S1](#mmc2){ref-type="supplementary-material"}). This correlated with a small decrease in *gata1* expression ([Figure S6](#mmc1){ref-type="supplementary-material"}B) and a large decrease in *o*-dianisidine staining at 48 hpf in *osmr* morphants ([Figure S6](#mmc1){ref-type="supplementary-material"}C). Furthermore, double transgenic *flk1:eGFP*;*gata1:DsRed osmr* morphants showed abnormal tail vasculature and reduced circulating red blood cells compared with control embryos at 48 hpf ([Figure S6](#mmc1){ref-type="supplementary-material"}D). However, primitive myelopoiesis was completely normal ([Figure S6](#mmc1){ref-type="supplementary-material"}E). We directly targeted *osm* expression by morpholino ([Figures S5](#mmc1){ref-type="supplementary-material"}E and S5F) and recapitulated the hematopoietic phenotypes observed in *osmr* morphants ([Figure 4](#fig4){ref-type="fig"}D). However, we did observe that the majority of *osm* morphants display normal *cmyb* expression at 36 hpf, indicating a recover from the reduction of *gata2b/runx1* expression ([Figure 4](#fig4){ref-type="fig"}D). We conclude that *osm* overexpression is sufficient to expand HSCs and that *osmr* signaling is necessary for HSC specification and primitive erythropoiesis, but not for primitive myelopoiesis. We next examined the synergistic effects of *osm* and *kitlgb* on HSC expansion and HSC emergence.Figure 4*osmr* Signaling Is Necessary for HSC Specification(A) *gata2b*, *runx1*, and *cmyb* ISH in control MO, or *osmr* MO-injected embryos (injected at 4 ng throughout, unless stated). Scale bar, 100 μm. ctl, control.(B) ISH expression of *cmyb*, in control MO, or *osmr* MO-injected embryos. Scale bar, 100 μm.(C) *rag1* expression in the thymus after control MO or *osmr* MO injection, along with quantification of thymus area. Data are box and whiskers, min to max. Scale bar, 50 μm.(D) *gata2b*, *runx1*, and *cmyb* ISH in control MO, or *osm* MO (injected at 7 ng throughout, unless stated)-injected embryos. Scale bar, 100 μm. Data are boxes and whiskers, min to max. Statistical analysis was completed using an unpaired, two-tailed Student\'s t test. ^∗∗∗∗^p \< 0.0001.

*osm* and *kitlgb* Synergistically Expand HSCs and Increase HSC Proliferation {#sec2.6}
-----------------------------------------------------------------------------

As we, and others, have found that *kita* plays a major role in pigmentation but not hematopoiesis ([@bib16], [@bib30]), we investigated any possible synergy between the *kitlgb/kitb* and *osm/osmr* pathways. The injection of subliminal doses of *kitlgb* and *osm* mRNA alone resulted in no change in *runx1* (28 hpf) or *cmyb* (4 dpf) expression ([Figures 5](#fig5){ref-type="fig"}A--B′). However, injecting both mRNAs into the same embryo resulted in a strong increase of *cmyb* (4 dpf) in the CHT, although *runx1* was not affected at 28 hpf ([Figures 5](#fig5){ref-type="fig"}A--5B′), which likely resulted from increased HSC proliferation in the CHT, as measured by pH3 staining ([Figures 5](#fig5){ref-type="fig"}C--5D′). We therefore conclude that these cytokines act synergistically to expand HSCs after they arrive in the CHT.Figure 5*osm* and *kitlgb* Signal Synergistically to Expand HSCs in the CHT(A) *runx1* ISH at 28 hpf in NI embryos and *kitlgb* or *osm* mRNA-injected embryos (injected separately and together) at subliminal doses. Scale bar, 100 μm.(B) *cmyb* ISH at 4 dpf in NI embryos and *kitlgb* or *osm* mRNA-injected embryos (injected separately and together) at subliminal doses. Scale bar, 100 μm.(B′) *cmyb* expression analysis. Analysis is Fisher\'s exact test. NI versus *kitlgb*, p = 0.29; NI versus *osm*, p = 0.48; NI versus *kitlgb* + *osm*, p = 0.0001.(C) Imaging schematic.(D) Immunofluorescence for GFP and pH3. Arrows represent double-positive, proliferating cells. Scale, 25 μm.(D′) Quantification of double-positive cells. (D′) Data are means ± SD and analysis is an ordinary one-way ANOVA with multiple comparisons. ANOVA p value = 0.0082. ^∗∗∗^p \< 0.001; ^∗∗^p \< 0.01; NS, p \> 0.05.

To further examine this synergistic effect, we co-injected morpholinos against *kitb* or *osmr*, at subliminal doses. Injections of each morpholino alone resulted in normal *runx1* at 28 hpf and *cmyb* expression at 4 dpf ([Figure 6](#fig6){ref-type="fig"}A--6B′). However, when injected together, a robust decrease in *runx1* at 28 hpf and *cmyb* at 4 dpf was observed ([Figures 6](#fig6){ref-type="fig"}A and 6B′). Altogether, these experiments show that both *kitb* and *osmr* signaling pathways act together to specify, and then expand, HSCs in the CHT ([Figure 6](#fig6){ref-type="fig"}C).Figure 6Inhibition of *osmr* and *kitb* Signaling Synergistically Inhibits HSC Specification(A) *runx1* (28 hpf) ISH following control MO, *osmr* MO, or *kitb* MO injection (separately and together) at subliminal doses (half doses). ctl, control.(B) *cmyb* ISH at 4 dpf following control MO, *osmr* MO, or *kitb* MO injection (separately and together) at subliminal doses (half doses). (B′) Quantification of the results observed in panel (B). High *cmyb*signal (black), medium *cmyb* signal (grey) and low *cmyb* signal (white). Analysis was generated by Fisher's exact test. NI versus *kitb-MO*; p = 0.082, NI versus *osmr-MO*; p = 0.0089, NI versus *kitb*+*osmr-MOs*; p = 0.0000009.(C) Summary. Aortic ECs transition to "HE/pro HSC" by expressing *gata2b*, a process that requires *osm*/*osmr* signaling. HSCs then begin to bud from the aorta and begin to express *runx1* to become "pre HSCs", a process that requires *kitlgb*/*kitb* signaling. HSC then become "HSCs" and express *cmyb*. HSCs migrate to the CHT and can either proliferate (prolif.) or differentiate (diff.) in response to cytokines expressed by caudal ECs (cECs). Some will differentiate to lymphoid lineages. Proliferation of HSCs is enhanced by *osm* and differentiation to lymphoid lineages is inhibited. HSC proliferation is also synergistically enhanced by both *kitlgb* and *osm* signaling through their receptors. ^∗∗∗∗^p \< 0.0001; ^∗∗^p \< 0.01. All scale bars, 100 μm. HE, hemogenic endothelium.

Discussion {#sec3}
==========

We have investigated *kit* signaling in zebrafish hematopoiesis and shown interesting functional differences between the *kit* and *kitlg* paralogs, despite their relative similarities. We found that *kita/kiltga* signaling is important for pigmentation but not for hematopoiesis, concordant with previous reports ([@bib16], [@bib30]). Furthermore, *kita* is expressed in neural crests and *sparse* (*kita*) mutants survive, are healthy, and only have reduced melanocyte numbers ([@bib30]). We also showed that *kitlgb/kitb* signaling is required for zebrafish hematopoiesis. Our data indicate that *kitlgb* preferentially signals through *kitb*, while *kitlga* signals through *kita*, but we cannot exclude any cross-activation of these ligands with the two receptors, as low levels of *kita* were detected in HSCs. A previous report showed that *kitlgb* is expressed within the posterior blood island, the tissue that will give rise to the CHT at 24 hpf ([@bib16]). As EMPs are born in this area, we also checked their numbers in *kitb* morphants but could not find any difference at 30 hpf (data not shown). However, *kitb* but not *kita* morphants showed a strong decrease of *runx1* along the aorta. Work in the mouse embryo has indicated that *Kit-L* was required, not for the initial specification of the hemogenic endothelium into pro-HSCs, but rather for the maturation and maintenance of HSCs in mouse AGM cultures ([@bib34]). Further studies have shown that cells at the base of aortic HSC clusters are highly proliferative and express higher levels of *c-Kit* ([@bib1]). As we found that *gata2b* is maintained, but *runx1* is lost, in *kitb* morphants, we conclude that, as in mammals, *kitb* signaling is not required for the initial specification of the hemogenic endothelium but rather for the maturation of pro-HSCs into *runx1/cmyb*-positive pre-HSCs, to follow the mouse nomenclature that has been proposed ([@bib34]). Moreover, *kitb* signaling seems to be also required for HSC expansion at later stages ([Figure 6](#fig6){ref-type="fig"}C).

However, as we previously described, the overexpression of *kitlgb* by itself cannot expand HSCs in the CHT ([@bib21]). Therefore, we started to investigate for potential cytokines that could act together with *kitlgb*. As mouse and human oncostatin M showed promising results ([@bib26], [@bib28]), we undertook to find the ortholog of this cytokine in the zebrafish genome. Based on synteny and sequence similarities, we established that *si:ch73-47f2.*1 was the most likely candidate. Moreover, our data indicate that targeting *si:ch73-47f2.*1 by morpholino induces the exact same phenotypes observed in *osmr* morphants. Altogether, our data suggest that *si:ch73-47f2.*1 is the zebrafish ortholog of *Oncostatin M*. However, we were unable to find orthologs of *si:ch73-47f2.*1 in many other closely related fish species (such as *Sinocyclocheilus rhinocerous* and medaka), although in many cases an ortholog for *osmr* is listed. This, coupled with the low amino acid similarity, raises the possibility that *si:ch73-47f2.*1 could encode a novel, zebrafish-specific regulator of hematopoiesis that would be related to, but distinct from, *osm*. We show that *osm* is expressed in the CHT vascular niche under the control of *tfec*, a transcription factor that also controls *kitlgb* expression ([@bib21]). Indeed, *osm* could rescue the HSC defect observed in *tfec* mutants and, in contrast to *kitlgb*, *osm* could increase the number of HSCs in the CHT, but we did not observe any increase of HSCs in the aorta, as was observed for mouse AGM-HSCs ([@bib23]). In the CHT, *osm* acted by increasing HSC proliferation, similarly to *tfec* gain of function, and we observed that this HSC expansion was accompanied by a reduction of lymphoid development. Indeed, we show here that *osm* downregulates *irf4a*, a transcription factor required for lymphopoiesis that also controls *ccr9a* expression ([@bib44]). Our results suggest that *osm* negatively regulates the expression of several lymphoid genes within lymphoid-primed progenitors. Our results corroborate a previous report showing that mouse *OSM* can inhibit the differentiation of HSCs toward the lymphoid lineage in the mouse fetal liver ([@bib19]). However, this study mainly focused on embryonic B cell lymphopoiesis ([@bib19]), whereas our results point to the effect of *osm* on T cell commitment. It is possible that *osm* mediates a similar effect upon B cell differentiation but, due to the late emergence of B lymphopoiesis in zebrafish (around 20 dpf) ([@bib29]), we could not test this hypothesis in our experiments. Furthermore, [@bib13] described that *OSM* deficiency led to a decreased thymic size and the accumulation of apoptotic thymocytes in the adult mouse. Zebrafish *osm* may also be required for thymic maintenance in a similar manner, as we show that the deficiency in the *osm* pathway decreases definitive hematopoiesis, therefore resulting in a smaller thymus.

We indeed found that *osmr* signaling is necessary for early HSC specification, as indicated by the loss of *gata2b*/*runx1* in *osmr* morphants. This role of *osm* might have been conserved throughout evolution. Indeed, *Osm* is expressed in the mouse AGM region, in the genital ridges and the sub-aortic mesenchyme ([@bib23]). Moreover, *Osmr* is highly enriched in ECs and newly formed hematopoietic progenitors from the human AGM but downregulated in fetal liver hematopoietic progenitors ([@bib25]). We therefore conclude that the *osm* signaling pathway is important for the emergence of HSCs ([Figure 6](#fig6){ref-type="fig"}C).

Finally, we tested a possible synergistic effect between both *osm/osmr* and *kitlgb/kitb* pathways, as it was previously demonstrated in the expansion of human HSCs ([@bib28]). We first showed that subliminal inhibition of both *osmr* and *kitb* receptors leads to a complete loss of HSC specification, whereas each morpholino on its own had no effect on HSC specification. As we show that the block induced in *osmr* morphants occurs at an earlier stage than the one induced by the *kitb* morpholino, we conclude that both signals are required sequentially for normal HSC specification. Concerning HSC expansion in the CHT, we have shown that *osm* and *kitlgb* overexpression is sufficient to expand hematopoiesis *in vivo*, which corroborates results gained from *in vitro* analysis on human HSCs ([@bib28]). Altogether, our data convincingly show that the *kit* pathway has been conserved in the zebrafish model to allow normal HSC development. Moreover, we show that it acts together with the *osm/osmr* pathway during HSC specification from the hemogenic endothelium and for the expansion phase in the CHT. Moreover, by modulating these two pathways, we could unravel discrete stages of HSC specification from the hemogenic endothelium. Further studies will be required to fully understand the precise sequence of events, as well as the source of the signals.

Experimental Procedures {#sec4}
=======================

Zebrafish Strains and Husbandry {#sec4.1}
-------------------------------

AB^∗^ (WT), along with transgenic and mutant strains, were kept in a 14/10 hr light/dark cycle at 28°C ([@bib45]). We used the following transgenic animals: *lmo2:eGFP*^*zf71*^ ([@bib46]), *gata1:DsRed*^*sd2*^ ([@bib42]), *flk1:eGFP*^*s843*^ ([@bib17]), *flk1:Hsa.HRAS-mCherry*^*s896*^ ([@bib8]), *cmyb:GFP*^*zf169*^ ([@bib27]), *ikaros:eGFP*^*fr101*^ ([@bib15]), *tfec*^*ug103*^ mutants ([@bib21]).

Whole-Mount *In Situ* Hybridization Staining and Analysis {#sec4.2}
---------------------------------------------------------

Whole-mount *in situ* hybridization (WISH) was performed on 4% paraformaldehyde (PFA)-fixed embryos at the developmental time points indicated. Digoxygenin labeled probes were synthesized using an RNA labeling kit (SP6/T7; Roche). RNA probes were generated by linearization of TOPO-TA or ZeroBlunt vectors (Invitrogen) containing the PCR-amplified cDNA sequence. WISH was performed as previously described ([@bib40]). Phenotypes were scored by comparing expression with siblings. All injections were repeated three independent times. Analysis was performed using GraphPad Prism software. Embryos were imaged in 100% glycerol using an Olympus MVX10 microscope. Oligonucleotide primers used for the production of ISH probes are listed in [Table S1](#mmc1){ref-type="supplementary-material"}.

*O*-Dianisidine Staining {#sec4.3}
------------------------

Embryos at 48 hpf were stained in 0.9 mg/mL o-dianisidine (Sigma), 10 mM sodium acetate (pH 4.5), 0.65% hydrogen peroxide, 60% ethanol for 25 min in the dark, and then fixed in 4% PFA for 1 hr at 4°C and imaged in 70% glycerol.

Cell Sorting and Flow Cytometry {#sec4.4}
-------------------------------

Zebrafish transgenic embryos (15--20 per biological replicate) were incubated in 0.5 mg/mL Liberase (Roche) solution and shaken for 90 min at 33°C, then dissociated, filtered, and resuspended in 0.9× PBS and 1% FCS. Dead cells were labeled and excluded by staining with 5 nM SYTOX red (Life Technologies) or 300 nM DRAQ7 (Biostatus). Cell sorting was performed using an Aria II (BD Biosciences) or a Bio-Rad S3. Data were analyzed using FlowJo and statistical analysis completed using Microsoft Excel or GraphPad Prism.

Real-Time qPCR and qPCR Analysis {#sec4.5}
--------------------------------

RNA was extracted using an RNeasy minikit (QIAGEN) and reverse transcribed into cDNA using a Superscript III kit (Invitrogen) or qScript (Quanta Biosciences). qPCR was performed using KAPA SYBR FAST Universal qPCR Kit (Kapa Biosystems) and run on a CFX Connect real-time system (Bio-Rad). All primers are listed in [Table S2](#mmc1){ref-type="supplementary-material"}. Analysis was performed using Microsoft Excel or Prism.

Synthesis of Full-Length mRNA and Microinjection {#sec4.6}
------------------------------------------------

PCR primers to amplify cDNA of interest are listed in [Table S1](#mmc1){ref-type="supplementary-material"}. *Tfec* mRNA was synthesized and injected as previously described ([@bib21]). mRNA was reverse transcribed using mMessage mMachine kit SP6 (Ambion) from a linearized pCS2^+^ vector containing PCR products. Following transcription, RNA was purified by phenol-chloroform extraction. *osm* mRNA was injected at 300 pg, unless otherwise stated.

Imaging {#sec4.7}
-------

WISH was imaged using an Olympus MVX10 microscope in 100% glycerol. Fluorescent images were taken with an Olympus IX83 microscope and processed using cellSens Dimension software. All images were processed using Adobe Photoshop.

Immunofluorescence Staining {#sec4.8}
---------------------------

Images were obtained with a Nikon SMZ1500 microscope or a Nikon inverted A1r spectral confocal microscope. Z stacks were made through the entire CHT during confocal imaging in multiple fluorescent channels. Immunofluorescence double staining was carried out and analyzed as described previously ([@bib14]), with chicken anti-GFP (1:400, Life Technologies, catalog no. A10262) and rabbit anti-phospho-histone 3 (pH3) antibodies (1:250, abcam, catalog no. ab5176). AlexaFluor488-conjugated anti-chicken secondary antibody (1:1,000, Life Technologies, catalog no A11039) and AlexaFluor594-conjugated anti-rabbit secondary antibody (1:1,000, Life Technologies, catalog no. A11012) were used to reveal primary antibodies.

Morpholinos {#sec4.9}
-----------

All morpholino oligonucleotides (MOs) were purchased from Gene Tools and are listed in [Table S3](#mmc1){ref-type="supplementary-material"}. MO efficiency was tested using qPCR from total RNA extracted from 10 embryos at 24 hpf. qPCR primers are listed in [Table S2](#mmc1){ref-type="supplementary-material"}. *osmr*, *kita*, and *kitb* morpholinos were injected at 4 ng, 3 ng, and 8 ng, respectively, unless otherwise stated. *Kitlgb* and *osm* MOs were injected at 5 ng and 7 ng, respectively, unless otherwise stated. *Kitlgb* MO efficiency was tested using full-length primers ([Table S1](#mmc1){ref-type="supplementary-material"}). *Osm* MO efficiency was tested using qPCR primers ([Table S2](#mmc1){ref-type="supplementary-material"}). All MOs used in this study are splice blocking MOs.
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